Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

Taroh Satoh, Kyung Hee Lee, Sun Young Rha, Yasutsuna Sasaki, Se Hoon Park, Yoshito Komatsu, Hirofumi Yasui, Tae You Kim, Kensei Yamaguchi, Nozomu Fuse, Yasuhide Yamada, Takashi Ura, Si Young Kim, Masaki Munakata, Soh Saitoh, Kazuto Nishio, Satoshi Morita, Eriko Yamamoto, Qingwei Zhang, Jung mi KimYeul Hong Kim, Yuh Sakata

Research output: Contribution to journalArticle

57 Citations (Scopus)

Fingerprint Dive into the research topics of 'Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences